SCHEMBL4925818

SCHEMBL4925818

CN(C)S(=O)(=O)c1ccc(CNC(=O)c2cc3cc(Cl)ccc3o2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.59
HDAC1 Q13547 3/20 0.59
HDAC2 Q92769 3/20 0.59
LMNA P02545 2/20 0.53
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
CLK1 P49759 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 4/20 0.50
BCAT1 P54687 1/20 0.50
ADAMTS4 O75173 1/20 0.48
ADAMTS5 Q9UNA0 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4927665 0.88 HDAC3 (0.62) HDAC3HDAC1HDAC2SMN1; SMN2ALDH1A1
SCHEMBL4925340 0.84 HDAC3 (0.64) HDAC3HDAC1HDAC2SMN1; SMN2ALDH1A1
SCHEMBL4927460 0.83 HDAC3 (0.67) HDAC3HDAC1HDAC2SMN1; SMN2ALDH1A1
SCHEMBL4925354 0.81 HDAC3 (0.69) HDAC3HDAC1HDAC2SMN1; SMN2ALDH1A1
SCHEMBL14270767 0.81 HDAC3 (0.65) HDAC3HDAC1HDAC2SMN1; SMN2ALDH1A1
SCHEMBL4927113 0.80 HDAC3 (0.64) HDAC3HDAC1HDAC2RAB9ANPC1
SCHEMBL4916668 0.80 TP53 (0.72) HDAC3HDAC1HDAC2LMNARAB9A
SCHEMBL4928945 0.80 HDAC3 (0.67) HDAC3HDAC1HDAC2SMN1; SMN2ALDH1A1
SCHEMBL4927036 0.80 HDAC3 (0.64) HDAC3HDAC1HDAC2ALDH1A1CYP2C9
SCHEMBL4925843 0.80 HDAC3 (0.64) HDAC3HDAC1HDAC2SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US claimed
EP-1838690-A2 COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY Devgen N.V. (BE) 2007-10-03 EP claimed
WO-2006066879-A2 COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY DEVGEN N.V. (BE) 2006-06-29 WO claimed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US disclosed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US disclosed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity KCNA4, HCN4, KCNN4 HDAC3 818/4885HDAC1 2126/4885HDAC2 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.